<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021263</url>
  </required_header>
  <id_info>
    <org_study_id>21D.499</org_study_id>
    <nct_id>NCT05021263</nct_id>
  </id_info>
  <brief_title>Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?</brief_title>
  <official_title>Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double blind controlled trial examining the impact of&#xD;
      incorporating a single intraoperative intravenous magnesium bolus and infusion into a&#xD;
      preexisting Enhanced Recovery After Surgery (ERAS) protocol for colorectal surgery in place&#xD;
      of preoperative oral pregabalin. These protocols are pathways designed with the goal of&#xD;
      achieving early surgical recovery by utilizing a constellation of perioperative care&#xD;
      techniques that include the use of opioid-sparing pain medications, minimally invasive&#xD;
      approaches, and prevention of post-operative nausea and vomiting, among others. Intravenous&#xD;
      magnesium has shown to be an effective non-opioid analgesic in abdominal surgeries that&#xD;
      decreases total opioid consumption, pain, and improves recovery. The purpose of this study is&#xD;
      to evaluate whether or not the addition of intravenous magnesium to our institutional ERAS&#xD;
      protocol will improve specific outcome measures, and provide additional benefits when&#xD;
      compared to oral preoperative pregabalin. The primary outcome is the patient's quality of&#xD;
      recovery based on the &quot;Quality of Recovery - 40 Questionnaire&quot; (QOR 40), and secondary&#xD;
      outcomes will be opioid consumption, pain, shivering, sedation scores, acute kidney injury,&#xD;
      gastrointestinal function, respiratory function, and hospital length of stay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery 40 Questionnaire</measure>
    <time_frame>Postoperative Day 0-2</time_frame>
    <description>Validated Assessment of Postoperative Recovery</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Magnesium Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The magnesium group (Mg) will receive a bolus of 50 mg/kg of IV magnesium prior to incision and an infusion of 15 mg/kg/hr, with no preoperative oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The pregabalin group (Pb) will receive preoperative pregabalin and no IV magnesium bolus and infusion. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group (Ct) will receive saline solution and no IV magnesium or oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Medications</intervention_name>
    <description>IV magnesium sulfate, used to replete magnesium stores</description>
    <arm_group_label>Magnesium Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GABA agonist</intervention_name>
    <description>Pregabalin (oral), current standard of care for ERAS</description>
    <arm_group_label>Pregabalin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective Laparoscopic Colorectal Surgery&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  ASA (American Society of Anesthesiologists) Physical Status Classification 1-3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of Buprenorphine/Suboxone or Methadone maintenance treatment&#xD;
&#xD;
          -  Known history of substance abuse&#xD;
&#xD;
          -  Use of intra- and/or postoperative Ketamine or Lidocaine infusion&#xD;
&#xD;
          -  Pre- or postoperative placement of Epidural catheter&#xD;
&#xD;
          -  Inability to speak English or communicate verbally&#xD;
&#xD;
          -  Chronic Kidney Disease (CKD) Stage 3&#xD;
&#xD;
          -  Hepatic Cirrhosis&#xD;
&#xD;
          -  Neuromuscular disease&#xD;
&#xD;
          -  Heart block on EKG&#xD;
&#xD;
          -  Uncontrolled diabetes with Hba1c &gt; 8%&#xD;
&#xD;
          -  Known allergies to study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin Min, MD</last_name>
    <phone>6314852542</phone>
    <email>kevin.min@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kevin Min</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Kevin Min</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>GABA Agonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

